U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C49H55NO14S
Molecular Weight 914.024
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-184476

SMILES

[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]4(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C5=CC=CC=C5)C6=CC=CC=C6)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@H](C[C@H]7OC[C@@]27OC(C)=O)OCSC)C4(C)C

InChI

InChIKey=UBJAHGAUPNGZFF-XOVTVWCYSA-N
InChI=1S/C49H55NO14S/c1-27-33(62-45(57)38(53)37(30-17-11-8-12-18-30)50-43(55)31-19-13-9-14-20-31)24-49(58)42(63-44(56)32-21-15-10-16-22-32)40-47(6,41(54)39(61-28(2)51)36(27)46(49,4)5)34(60-26-65-7)23-35-48(40,25-59-35)64-29(3)52/h8-22,33-35,37-40,42,53,58H,23-26H2,1-7H3,(H,50,55)/t33-,34-,35+,37-,38+,39+,40-,42-,47+,48-,49+/m0/s1

HIDE SMILES / InChI

Description

Bristol-Myers Squibb developed BMS-184476 for the potential treatment of solid tumors. BMS-184476 participated in phase II clinical trials for patients with non-small-cell lung cancer, breast, and ovarian cancers. However, that development has been discontinued.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
Fifty-six previously treated advanced NSCLC patients received BMS-184476 at a dose of 60 mg/m(2) administered intravenously over 1 h every 21 days.
Route of Administration: Intravenous